U.S. markets closed

Travere Therapeutics, Inc. (TVTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.90-0.11 (-0.73%)
At close: 4:00PM EDT
14.90 0.00 (0.00%)
After hours: 04:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close15.01
Open14.93
Bid14.88 x 800
Ask14.90 x 800
Day's Range14.51 - 15.01
52 Week Range13.85 - 33.09
Volume484,870
Avg. Volume713,271
Market Cap900.82M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

    NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the clas

  • Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021
    GlobeNewswire

    Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

    SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high affinity antagonist of both endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, in focal segmental glomerulosclerosis (FSGS) mouse models, at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress. The Company and its collaborators will a

  • Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
    GlobeNewswire

    Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

    Topline data from interim 36-week proteinuria endpoint expected in August 2021SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week prote